Status:
COMPLETED
Fertility Preservation in Women Who Will Have Gonadotoxic Therapy or Hematopoetic Stem Cell Transplantation, and in Women With Sickle Cell Disease
Lead Sponsor:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Conditions:
Hemoglobin
Stem Cell Transplant
Eligibility:
All Genders
7-45 years
Brief Summary
Background: \- Some treatments for cancer or other diseases can lead to infertility in women. These treatments include chemotherapy, some stem cell transplants, and pelvic radiotherapy. They are call...
Detailed Description
Treatment with chemotherapeutic drugs, hematopoietic stem cell transplantation, and pelvic radiotherapy for cancer or other serious medical illnesses has the potential to markedly increase the risk of...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Subject is able to give consent/assent to participate in the protocol:
- Post-Menarchal females greater than or equal to 7 years old undergoing gonadotoxic therapy, hematopoietic stem cell transplantation, and/or sickle cell disease
- Have a FSH less than or equal to 13 mIU/ml or AMH greater than or equal to 0.5 ng/ml
- EXCLUSION CRITERIA:
- Unable to comprehend the investigational nature of the protocol
- Positive pregnancy test
- Ovarian cancer
- Diagnosis of HIV/AIDS
Exclusion
Key Trial Info
Start Date :
August 15 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 20 2017
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT02225145
Start Date
August 15 2014
End Date
September 20 2017
Last Update
June 1 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892